Heart rate and use of beta-blockers in Mexican stable outpatients with coronary artery disease

被引:5
作者
Antonio Alcocer-Gamba, Marco [1 ,2 ,3 ]
Martinez-Sanchez, Carlos [3 ,4 ]
Verdejo-Paris, Juan [3 ,4 ]
Ferrari, Roberto [5 ,6 ,7 ]
Fox, Kim [8 ]
Greenlaw, Nicola [9 ]
Steg Philippe, Gabriel [8 ,10 ,11 ,12 ]
机构
[1] Inst Corazon Queretaro, Queretaro, Mexico
[2] Nacl CLARIFY, Queretaro, Mexico
[3] Soc Mexicana Cardiol, Mexico City, DF, Mexico
[4] Inst Nacl Cardiol Ignacio Chavez, Cd Mexico, Mexico
[5] Univ Hosp Ferrara, Dept Cardiol, Cotignola, Italy
[6] Univ Hosp Ferrara, LTTA Ctr, Cotignola, Italy
[7] ES Hlth Sci Fdn, Maria Cecilia Hosp, GVM Care & Res, Cotignola, Italy
[8] NHLI Imperial Coll, Royal Brompton Hosp, ICMS, London, England
[9] Univ Glasgow, Glasgow, Lanark, Scotland
[10] INSERM, U698, Paris, France
[11] Univ Paris Diderot, Paris, France
[12] Hop Bichat Claude Bernard, AP HP, Paris, France
来源
ARCHIVOS DE CARDIOLOGIA DE MEXICO | 2015年 / 85卷 / 04期
关键词
Heart rate; beta-Blockers; Stable coronary artery disease; Mexico;
D O I
10.1016/j.acmx.2015.01.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate the use of beta-blockers and to monitor heart rate in Mexican patients with coronary artery disease. Methods: CLARIFY is an outpatients registry with stable CAD. A total of 33,283 patients from 45 countries were enrolled between November 2009 and July 2010 from which 1342 were Mexican patients. Results: The mean HR pulse was 70 bpm (beats per minute). Patients in Mexico were compared with the remaining global CLARIFY population. Patients in Mexico had a higher incidence of acute myocardial infarction and percutaneous coronary intervention, and lower incidence of revascularization surgery compared with the remaining CLARIFY population. More often, Mexican patients presented with diabetes, but less often hypertension and stroke. These patients were split into three mutually exclusive groups of HR <= 60 (N = 263), HR 61-69 (N = 356) and HR >= 70 (N = 722). Patients with elevated HR had a higher incidence of diabetes and higher diastolic blood pressure on average than those with controlled HR. Regarding the use of beta-blockers, they were used in 63.3% of patients, 2.7% showed intolerance or contraindication to treatment to monitor heart rate, and ivabradine was used in 2.3%. Out of approximately 849 patients receiving treatment of beta-blockers, 52.1% had >= 70 bpm HR. Conclusions: In a large proportion of Mexican patients with stable coronary disease the HR remain elevated, >70 bpm, even with the use of beta-blockers; this requires further attention. (C) 2014 Instituto Nacional de Cardiologia Ignacio Chavez. Published by Masson Doyma Mexico S. A. All rights reserved.
引用
收藏
页码:270 / 277
页数:8
相关论文
共 24 条
  • [1] Expanding priorities - Confronting chronic disease in countries with low income
    Anderson, Gerard F.
    Chu, Edward
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (03) : 209 - 211
  • [2] Influence of heart rate on mortality in a French population - Role of age, gender, and blood pressure
    Benetos, A
    Rudnichi, A
    Thomas, F
    Safar, M
    Guize, L
    [J]. HYPERTENSION, 1999, 33 (01) : 44 - 52
  • [3] Bohm M, 2010, LANCET, V376, P886, DOI 10.1016/S0140-6736(10)61259-7
  • [4] Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina -: A randomized, double-blind, multicentered, placebo-controlled trial
    Borer, JS
    Fox, K
    Jaillon, P
    Lerebours, G
    [J]. CIRCULATION, 2003, 107 (06) : 817 - 823
  • [5] Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease
    Diaz, A
    Bourassa, MG
    Guertin, MC
    Tardif, JC
    [J]. EUROPEAN HEART JOURNAL, 2005, 26 (10) : 967 - 974
  • [6] Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
    Fox, Kim
    Ford, Ian
    Steg, P. Gabriel
    Tendera, Michal
    Ferrari, Roberto
    [J]. LANCET, 2008, 372 (9641) : 807 - 816
  • [7] Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
    Fox, Kim
    Ford, Ian
    Steg, P. Gabriel
    Tendera, Michal
    Robertson, Michele
    Ferrari, Roberto
    [J]. LANCET, 2008, 372 (9641) : 817 - 821
  • [8] Resting heart rate in cardiovascular disease
    Fox, Kim
    Borer, Jeffrey S.
    Camm, A. John
    Danchin, Nicolas
    Ferrari, Roberto
    Lopez Sendon, Jose L.
    Steg, Philippe Gabriel
    Tardif, Jean-Claude
    Tavazzi, Luigi
    Tendera, Michal
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (09) : 823 - 830
  • [9] Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial
    Fox, Kim
    Ford, Ian
    Steg, Ph. Gabriel
    Tendera, Michal
    Robertson, Michele
    Ferraris, Roberto
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 (19) : 2337 - 2345
  • [10] β Blockade after myocardial infarction:: systematic review and meta regression analysis
    Freemantle, N
    Cleland, J
    Young, P
    Mason, J
    Harrison, J
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1999, 318 (7200): : 1730 - 1737